1期实体瘤生物技术公司Aktis Oncology(AKTS.US)申请美股IPO 拟筹资1亿美元

Core Viewpoint - Aktis Oncology, a clinical-stage biotech company focused on developing targeted radiopharmaceuticals for solid tumors, has filed for an IPO to raise up to $100 million [1][2] Group 1: Company Overview - Aktis Oncology was founded in 2020 and is headquartered in Boston, Massachusetts [2] - The company specializes in α-particle emitting radiopharmaceuticals aimed at treating high-prevalence solid tumors [1] Group 2: Product Pipeline - The lead candidate, Ac-AKY-1189, targets Nectin-4 protein-expressing cancers and is currently undergoing a multi-center Phase Ib clinical trial in the U.S. with approximately 150 patients enrolled; preliminary clinical data is expected in Q1 2027 [1] - Another candidate, Ac-AKY-2519, targets B7-H3 protein-expressing tumors, with an Investigational New Drug (IND) application planned for submission in 2026 [1] Group 3: Financial Information - For the 12 months ending September 30, 2025, the company expects to achieve revenue of $6 million [2] - The IPO will be listed on NASDAQ under the ticker symbol AKTS, with joint bookrunners including JPMorgan, Bank of America Securities, Leerink Partners, and TD Cowen [2]